The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
New Oral Anticoagulants in Elderly Adults: Evidence from a Meta‐Analysis of Randomized Trials
Abstract
Objectives: To evaluate the efficacy and safety of new oral anticoagulants ( NOAC s) in elderly adults. Design: Meta‐analyses of randomized clinical trials ( RCT s). Setting: PubMed, C ochrane L ibrary, EMBASE , W eb of S cience, and CINAHL databases were searched from J anuary 1, 2001, through M arch 30, 2013. Participants: Elderly population (≥75) in RCT s comparing NOAC s (rivaroxaban, apixaban, and dabigatran) with conventional therapy. Measurements: Two authors reviewed the trials, and odds ratios ( OR s) were calculated using a random effects model. Results: Ten RCT s included 25,031 elderly participants. Risk of major or clinically relevant bleeding was not significantly different between NOAC s and conventional therapy in elderly adults ( OR = 1.02, 95% confidence interval = 0.73–1.43). Similar results were observed when comparing NOAC s and pharmacologically active agents. In atrial fibrillation ( AF ) trials, NOAC s were more effective than conventional therapy in prevention of stroke or systemic embolism in an elderly population with AF . In non‐ AF trials, NOAC s also had a significantly lower risk of venous thromboembolism ( VTE ) or VTE ‐related death than conventional therapy in elderly adults. Analysis for individual NOAC s showed that the NOAC was noninferior or more effective than conventional therapy for efficacy and safety outcomes. Conclusion: In participants of clinical trials aged 75 and older, NOAC s did not cause excess bleeding and were associated with equal or greater efficacy than conventional therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00136 · Cited by 10,349
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Atrial fibrillation as an independent risk factor for stroke: the Framingham study
Wolf, P. A., Abbott, R. D., & Kannel, W. B. (1991) · Stroke · doi:10.1161/01.str.22.8.983 · Cited by 7,388
Lip, G. Y. H., Nieuwlaat, R., Pisters, R., Lane, D. A., & Crijns, H. J. G. M. (2010) · Chest · doi:10.1378/chest.09-1584 · Cited by 6,879
Self-citationKearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
SCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Assessing Risk of Bias in Included Studies
Higgins, J. P., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch8 · Cited by 3,396
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Apixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Effect of clopidogrel added to aspirin in patients with atrial fibrillation
The ACTIVE Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901301 · Cited by 2,102
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
Mega, J. L., Braunwald, E., Wiviott, S. D., Bassand, J.-P., Bhatt, D. L., Bode, C., Burton, P., Cohen, M., Cook-Bruns, N., Fox, K. A. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112277 · Cited by 1,897
Ageno, W., Gallus, A. S., Wittkowsky, A., Crowther, M., Hylek, E. M., & Palareti, G. (2012) · Chest · doi:10.1378/chest.11-2292 · Cited by 1,503
Apixaban for Extended Treatment of Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1207541 · Cited by 1,366
Full accounting of diabetes and pre-diabetes in the U.S. population in 1988–1994 and 2005–2006
Cowie, C. C., Rust, K. F., Ford, E. S., Eberhardt, M. S., Byrd-Holt, D. D., Li, C., Williams, D. E., Gregg, E. W., Bainbridge, K. E., Saydah, S. H., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1296 · Cited by 1,154
Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Schellong, S., Eriksson, H., Baanstra, D., Kvamme, A. M., Friedman, J., Mismetti, P., & Goldhaber, S. Z. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1113697 · Cited by 983
Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
Cohen, A. T., Spiro, T. E., Büller, H. R., Haskell, L., Hu, D., Hull, R., Mebazaa, A., Merli, G., Schellong, S., Spyropoulos, A. C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1111096 · Cited by 607
Halperin, J. L., Hankey, G. J., Wojdyla, D. M., Piccini, J. P., Lokhnygina, Y., Patel, M. R., Breithardt, G., Singer, D. E., Becker, R. C., Hacke, W., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005008 · Cited by 431
Larsen, T. B., Rasmussen, L. H., Skjøth, F., Due, K. M., Callréus, T., Rosenzweig, M., & Lip, G. Y. H. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.03.020 · Cited by 403
Self-citationDentali, F., Riva, N., Crowther, M., Turpie, A. G. G., Lip, G. Y. H., & Ageno, W. (2012) · Circulation · doi:10.1161/circulationaha.112.115410 · Cited by 380
Self-citationVenous thrombosis in the elderly: incidence, risk factors and risk groups
ENGBERS, M. J., VAN HYLCKAMA VLIEG, A., & ROSENDAAL, F. R. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03986.x · Cited by 362
Dabigatran and Postmarketing Reports of Bleeding
Southworth, M. R., Reichman, M. E., & Unger, E. F. (2013) · New England Journal of Medicine · doi:10.1056/nejmp1302834 · Cited by 353
Bleeding Risk with Dabigatran in the Frail Elderly
Harper, P., Young, L., & Merriman, E. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1112874 · Cited by 285
The Use of Dabigatran in Elderly Patients
Legrand, M. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.314 · Cited by 204
Improving Stroke Risk Stratification in Atrial Fibrillation
Lip, G. Y. H., & Halperin, J. L. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.013 · Cited by 185
Self-citationDabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study
Sørensen, R., Gislason, G., Torp-Pedersen, C., Olesen, J. B., Fosbøl, E. L., Hvidtfeldt, M. W., Karasoy, D., Lamberts, M., Charlot, M., Køber, L., et al. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-002758 · Cited by 184
Self-citationFox, B. D., Kahn, S. R., Langleben, D., Eisenberg, M. J., & Shimony, A. (2012) · BMJ · doi:10.1136/bmj.e7498 · Cited by 138
Use of anticoagulants in elderly patients: practical recommendations
Righini, M. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s4308 · Cited by 133
Dabigatran-Induced Gastrointestinal Bleeding in an Elderly Patient with Moderate Renal Impairment
Wychowski, M. K., & Kouides, P. A. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q747 · Cited by 104
New anticoagulant treatments to protect against stroke in atrial fibrillation
Potpara, T., Lip, G. Y. H., & Apostolakis, S. Z. (2012) · Heart · doi:10.1136/heartjnl-2012-301841 · Cited by 41
Self-citationNew Oral Anticoagulants in Elderly Patients with Atrial Fibrillation
DEEDWANIA, P. C. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.10.012 · Cited by 39
Management of Venous Thromboembolism in the Elderly
Spyropoulos, A. C., & Merli, G. J. (2006) · Drugs & Aging · doi:10.2165/00002512-200623080-00003 · Cited by 33
Zarraga, I. G. E., & Kron, J. (2012) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12042 · Cited by 32
Cited by
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Self-citationHindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström-Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P. E., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 9,971
Self-citation2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
Andrade, J. G., Aguilar, M., Atzema, C., Bell, A., Cairns, J. A., Cheung, C. C., Cox, J. L., Dorian, P., Gladstone, D. J., Healey, J. S., et al. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.09.001 · Cited by 562
Metadata
- Authors
- Sardar, P., Chatterjee, S., Chaudhari, S., & Lip, G. Y. H.
- Venue
- Journal of the American Geriatrics Society
- Publisher
- Wiley
- Published
- 2014-05
- Volume
- 62
- Issue
- 5
- Pages
- 857-864
- ISSN
- 0002-8614 (ISSN-L)
- 1532-5415
- OpenAlex
- W2043351648
- Cited by
- 267
- References
- 39
- FWCI
- 24.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.